CClinicalTrials.gg
RecruitingNCT07496086Updated Mar 27, 2026

External Oblique Intercostal Block Versus Transversus Abdominis Plane Combined With Rectus Sheath Block on Postoperative Pain in Laparoscopic Radical Gastrectomy

An interventional study of EOIB and TAP+RSB in Postoperative Pain, sponsored by General Hospital of Ningxia Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by General Hospital of Ningxia Medical University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Postoperative pain is highly prevalent following laparoscopic radical gastrectomy. Although Transversus abdominis plane block combined with rectus sheath block(TAP+RSB) can effectively alleviate this pain, it still has many limitations. The external oblique intercostal plane block (EOIB) is a novel nerve block technique that may provide well postoperative analgesia for upper abdominal surgery. Therefore, this study employs a non-inferiority randomized controlled trial design to verify that the analgesic effect of EOIB is not inferior to that of ESPB, thereby offering more options for regional analgesia strategies in laparoscopic radical gastrectomy.

Read the detailed description

Laparoscopic radical gastrectomy (including subtotal and total gastrectomy) is the most commonly used surgical approach for gastric cancer. Although this technique is less invasive than traditional open surgery, more than 50% of patients still experience moderate to severe acute pain in the early postoperative period, making effective postoperative pain management essential. Regional nerve blockade techniques have become a key component of postoperative analgesia due to their reliable analgesic effect and significant reduction in opioid consumption.

The transversus abdominis plane block combined with rectus sheath block(TAP+RSB) is considered a relatively safe nerve block for upper abdominal surgery analgesia. However, the spread of the local anesthetic and the resulting block effect are unpredictable.

The external oblique intercostal plane block (EOIB) is a recently proposed regional block technique for the upper abdomen. This block involves injecting local anesthetic into the superficial fascial plane between the external oblique muscle and the intercostal muscles, thereby blocking the anterior rami and cutaneous branches of the intercostal nerves from T6-T10, which can provide effective analgesia for upper abdominal incision areas.

Nevertheless, current research on the analgesic effect of EOIB after laparoscopic radical gastrectomy remains limited, particularly lacking high-quality, prospective, randomized controlled studies to verify whether EOIB can achieve analgesic effects comparable to those of TAP+RSB, Therefore, this study adopts a non-inferiority randomized controlled trial design to verify that the postoperative analgesic effect of EOIB is better than TAP+RSB, providing more options for regional analgesia strategies in laparoscopic radical gastrectomy.

02

Conditions studied

  • Postoperative Pain

Browse trials for

03

In context

Pain, Postoperative

5,089 studies on the registry are indexed under Pain, Postoperative; 1,137 are open to participants now.

This study's planned enrollment of 100 is above the median of 75 across 4,341 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

General Hospital of Ningxia Medical University is the lead sponsor of 102 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients aged over 18 years
  • Classified as ASA I-III
  • Scheduled for elective laparoscopic radical gastrectomy under general anesthesia
  • Voluntarily participated and provided written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Chronic opioid dependence or prior use of analgesic medications for >3 months;
  • Inability to communicate due to severe dementia, language barriers, or terminal illness;
  • History of central and/or peripheral nervous system disorders;
  • Severe renal insufficiency (serum creatinine >442 μmol/L or requiring renal replacement therapy) or severe hepatic insufficiency (Child-Pugh class C);
  • Allergy to local anesthetics.
  • Expected to be transferred to ICU after surgery.
  • Refuse patient control agenesia after surgery.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    EOIB

    After patients entering the operating room, an intravenous line was established, and External Oblique Intercostal Plane Block was performed under ultrasound guidance.

    Procedure: EOIB

  • Experimental
    TAP+RSB

    After patients entering the operating room, an intravenous line was established, and Transversus abdominis plane block combined with rectus sheath block was performed under ultrasound guidance.

    Procedure: TAP+RSB

Interventions

  • ProcedureEOIB

    With the patient in the supine position, a high-frequency linear array probe (6-15 MHz) is used to perform a sagittal parasagittal oblique scan at the level of the 6th rib, between the right anterior axillary line and midclavicular line. The external oblique muscle, intercostal muscles, and ribs are identified. Using an in-plane technique, a 21G, 100mm block needle is inserted from a superomedial to inferolateral direction, with the needle tip positioned in the plane between the external oblique muscle and the intercostal muscles at the caudal edge of the 6th rib. 30ml of 0.375% ropivacaine is injected on each side, for a bilateral administra

  • ProcedureTAP+RSB

    With the patient in the supine position, above the umbilicus, a linear ultrasound transducer was positioned transversely on the rectus abdominis muscle, and 15 mL of ropivacaine 0.375% was injected into both sides of the aspect between the rectus abdominis muscle and the posterior rectus sheath with a 22G 70-mm block needle using the in-plane technique. At the midaxillary line, a linear ultrasound transducer was positioned close and parallel to the lower costal margin. In the bilateral aspect between the internal oblique and transversus abdominis muscles, 15 mL of ropivacaine 0.375% was injected on each side with a 22G 70-mm block needle.

06

What researchers measure

Primary outcomes

  1. Cumulative opioid consumption within 24 hours postoperatively

    Cumulative opioid consumption within 24 hours postoperatively. Conversion to morphine equivalent dose (mg)

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Pain Intensity

    Pain at rest and during coughing will be assessed using the Numerical Rating Scale (NRS, 0-10) at 2, 6, 12, 24, 48, and 72 hours postoperatively.0 represents no pain, and 10 represents the most pain.

    Time frame: 2, 6, 12, 24, 48, and 72 hours postoperatively

  2. Quality of Recovery

    The 15-item Quality of Recovery scale (QoR-15) was used for assessment at 24, 48, and 72 hours postoperatively. The higher the score, the better the recovery quality

    Time frame: 24,48,72 hours after surgery

  3. sleep quality

    Sleep quality was assessed using the Richards-Campbell Sleep Questionnaire (RCSQ) on postoperative nights.0 points represent very poor sleep, while 100 points represent very good sleep

    Time frame: 24,48,72 hours after surgery

07

Study locations

1 of 1 sites recruiting
  • General hospital of Ningxia medical university
    Yinchuan, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07496086
Lead sponsor
General Hospital of Ningxia Medical University
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Mar 20, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Nov 3, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

lingzi Yin, Doctoral
Contact
eleven87670@163.com
86-951-674-3252
lingzi Yin
study director · General hospital of Ningxia medical university, Yinchuan, Ningxia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion